JP2008530138A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008530138A5 JP2008530138A5 JP2007555370A JP2007555370A JP2008530138A5 JP 2008530138 A5 JP2008530138 A5 JP 2008530138A5 JP 2007555370 A JP2007555370 A JP 2007555370A JP 2007555370 A JP2007555370 A JP 2007555370A JP 2008530138 A5 JP2008530138 A5 JP 2008530138A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- antibody
- seq
- skin
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 6
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 6
- 210000001744 T-lymphocyte Anatomy 0.000 claims 5
- 206010012438 Dermatitis atopic Diseases 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 201000008937 atopic dermatitis Diseases 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 102100031547 HLA class II histocompatibility antigen, DO alpha chain Human genes 0.000 claims 3
- 101000866278 Homo sapiens HLA class II histocompatibility antigen, DO alpha chain Proteins 0.000 claims 3
- 208000003251 Pruritus Diseases 0.000 claims 3
- 210000004698 lymphocyte Anatomy 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 230000003213 activating effect Effects 0.000 claims 1
- 230000013727 interleukin-31 production Effects 0.000 claims 1
- 230000001823 pruritic effect Effects 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65311405P | 2005-02-14 | 2005-02-14 | |
| US60/653,114 | 2005-02-14 | ||
| US71676205P | 2005-09-13 | 2005-09-13 | |
| US60/716,762 | 2005-09-13 | ||
| US74995205P | 2005-12-13 | 2005-12-13 | |
| US60/749,952 | 2005-12-13 | ||
| PCT/US2006/005328 WO2006088956A2 (en) | 2005-02-14 | 2006-02-14 | Methods of predicting therpeutic response in atopic dermatitis to il-31 antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008530138A JP2008530138A (ja) | 2008-08-07 |
| JP2008530138A5 true JP2008530138A5 (https=) | 2009-04-09 |
| JP4927762B2 JP4927762B2 (ja) | 2012-05-09 |
Family
ID=36685803
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007555370A Expired - Fee Related JP4927762B2 (ja) | 2005-02-14 | 2006-02-14 | Ｉｌ−３１アンタゴニストに対するアトピー性皮膚炎の治療応答を予測する方法 |
| JP2007555369A Pending JP2008530137A (ja) | 2005-02-14 | 2006-02-14 | 皮膚リンパ球抗原陽性細胞により仲介される疾患を治療するための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007555369A Pending JP2008530137A (ja) | 2005-02-14 | 2006-02-14 | 皮膚リンパ球抗原陽性細胞により仲介される疾患を治療するための方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (11) | US20060188500A1 (https=) |
| EP (2) | EP1856150A2 (https=) |
| JP (2) | JP4927762B2 (https=) |
| AU (2) | AU2006214325B2 (https=) |
| CA (2) | CA2595939C (https=) |
| IL (3) | IL184734A (https=) |
| MX (2) | MX2007009471A (https=) |
| WO (2) | WO2006088956A2 (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE455852T1 (de) | 1999-06-02 | 2010-02-15 | Chugai Pharmaceutical Co Ltd | Neues hämopoietin rezeptorprotein nr10 |
| WO2001023556A1 (en) | 1999-09-27 | 2001-04-05 | Chugai Seiyaku Kabushiki Kaisha | Novel hemopoietin receptor protein, nr12 |
| ATE401390T1 (de) | 2002-01-18 | 2008-08-15 | Zymogenetics Inc | Zytokin (zcytor17-ligand) |
| US10080779B2 (en) | 2004-12-15 | 2018-09-25 | Universite D'angers | Method for increasing the expression of anti-microbial peptides by keratinocytes comprising administering a composition comprising IL-17, TNF-alpha and OSM |
| CA2594502A1 (en) * | 2005-01-28 | 2006-08-03 | Zymogenetics Inc. | Homogeneous preparations of il-31 |
| JP2008530132A (ja) | 2005-02-14 | 2008-08-07 | ザイモジェネティクス， インコーポレイテッド | Ｉｌ−３１ｒａアンタゴニストを用いて皮膚障害を治療する方法 |
| US20060188500A1 (en) | 2005-02-14 | 2006-08-24 | Leung Donald Y | Methods of predicting therpeutic response in atopic dermatitis to IL-31 antagonists |
| CN102321174B (zh) | 2005-05-06 | 2013-10-16 | 津莫吉尼蒂克斯公司 | Il-31单克隆抗体及使用方法 |
| US8101183B2 (en) | 2005-05-06 | 2012-01-24 | Zymogentics, Inc. | Variable region sequences of IL-31 monoclonal antibodies |
| US20130216542A1 (en) | 2005-05-06 | 2013-08-22 | Zymogenetics, Inc. | Variable region sequences of il-31 monoclonal antibodies and methods of use |
| WO2007133816A2 (en) | 2006-01-10 | 2007-11-22 | Zymogenetics, Inc. | Methods of treating pain and inflammation in neuronal tissue using il-31ra and osmrb antagonists |
| WO2007142325A1 (ja) | 2006-06-08 | 2007-12-13 | Chugai Seiyaku Kabushiki Kaisha | 炎症性疾患の予防または治療剤 |
| DK2594586T3 (en) * | 2006-09-01 | 2014-11-17 | Zymogenetics Inc | Monoclonal il-31 antibodies and methods of use thereof |
| US7799323B2 (en) | 2007-01-10 | 2010-09-21 | Zymogenetics, Inc. | Methods of using IL-31 to treat airway hyper-responsiveness and asthma |
| CN104162155A (zh) | 2007-12-05 | 2014-11-26 | 中外制药株式会社 | 搔痒症治疗药 |
| EP2796466B1 (en) | 2007-12-07 | 2017-11-22 | ZymoGenetics, Inc. | Humanized antibody molecules specific for IL-31 |
| US8790651B2 (en) | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| TW201537175A (zh) * | 2013-06-28 | 2015-10-01 | Chugai Pharmaceutical Co Ltd | 預測罹患具皮膚搔癢之疾病的患者對ｉｌ－３１拮抗劑之治療的反應之方法 |
| MA40824A (fr) * | 2014-10-22 | 2017-08-29 | Saiba Gmbh | Particules de cmv de type virus modifié |
| KR20170134748A (ko) | 2015-04-14 | 2017-12-06 | 추가이 세이야쿠 가부시키가이샤 | Il-31 안타고니스트를 유효 성분으로서 함유하는 아토피성 피부염의 예방용 및/또는 치료용 의약 조성물 |
| US10060273B2 (en) | 2015-04-15 | 2018-08-28 | United Technologies Corporation | System and method for manufacture of abrasive coating |
| WO2018156180A1 (en) | 2017-02-24 | 2018-08-30 | Kindred Biosciences, Inc. | Anti-il31 antibodies for veterinary use |
| AU2019236328B2 (en) | 2018-03-16 | 2025-10-09 | Zoetis Services Llc | Peptide vaccines against Interleukin-31 |
| CA3093539A1 (en) | 2018-03-16 | 2019-09-19 | Zoetis Services Llc | Interleukin-31 monoclonal antibodies for veterinary use |
| IL326629A (en) * | 2018-04-25 | 2026-04-01 | Kiniksa Pharmaceuticals Ltd | Treatment of skin diseases or disorders through administration of anti-OSMR BETA antibody |
| CN112190708B (zh) * | 2019-07-08 | 2023-09-05 | 上海交通大学医学院附属瑞金医院 | 趋化因子受体ccr6抑制剂在预防银屑病复发中的新应用 |
| RU2707181C1 (ru) * | 2019-08-15 | 2019-11-25 | федеральное государственное бюджетное образовательное учреждение высшего образования "Башкирский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Способ прогнозирования степени тяжести течения пруриго методом определения уровня концентрации триптазы в крови |
| CN114728064B (zh) | 2019-11-20 | 2025-05-06 | 中外制药株式会社 | 含抗体制剂 |
| KR102392954B1 (ko) * | 2020-02-11 | 2022-05-02 | 연세대학교 산학협력단 | 아토피 피부염 동물 모델인 아바타마우스의 제조 방법 및 그의 용도 |
| US20230391878A1 (en) | 2020-09-01 | 2023-12-07 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition for prevention and/or treatment of dialysis pruritus containing il-31 antagonist as active ingredient |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5792850A (en) * | 1996-05-23 | 1998-08-11 | Zymogenetics, Inc. | Hematopoietic cytokine receptor |
| US20040235955A1 (en) | 2001-09-14 | 2004-11-25 | Masami Narita | Remedies for pruritus |
| ATE401390T1 (de) | 2002-01-18 | 2008-08-15 | Zymogenetics Inc | Zytokin (zcytor17-ligand) |
| AU2003280410B8 (en) * | 2002-01-18 | 2009-04-23 | Zymogenetics, Inc. | Cytokine receptor zcytor17 multimers |
| JP2004219390A (ja) * | 2002-02-22 | 2004-08-05 | Taisho Pharmaceut Co Ltd | アトピー性皮膚炎に対し鎮痒効果を有する薬物の評価方法 |
| JPWO2003070252A1 (ja) | 2002-02-22 | 2005-06-09 | 大正製薬株式会社 | 止痒剤 |
| JP2004107209A (ja) * | 2002-09-13 | 2004-04-08 | Nippon Oruganon Kk | 掻痒治療薬 |
| JP4503942B2 (ja) * | 2003-06-11 | 2010-07-14 | 大正製薬株式会社 | 止痒剤 |
| RU2346996C2 (ru) | 2004-06-29 | 2009-02-20 | ЮРОПИЭН НИКЕЛЬ ПиЭлСи | Усовершенствованное выщелачивание основных металлов |
| CA2594502A1 (en) | 2005-01-28 | 2006-08-03 | Zymogenetics Inc. | Homogeneous preparations of il-31 |
| JP2008530132A (ja) * | 2005-02-14 | 2008-08-07 | ザイモジェネティクス， インコーポレイテッド | Ｉｌ−３１ｒａアンタゴニストを用いて皮膚障害を治療する方法 |
| US20060188500A1 (en) | 2005-02-14 | 2006-08-24 | Leung Donald Y | Methods of predicting therpeutic response in atopic dermatitis to IL-31 antagonists |
| US8101183B2 (en) | 2005-05-06 | 2012-01-24 | Zymogentics, Inc. | Variable region sequences of IL-31 monoclonal antibodies |
| CN102321174B (zh) * | 2005-05-06 | 2013-10-16 | 津莫吉尼蒂克斯公司 | Il-31单克隆抗体及使用方法 |
| WO2007037137A1 (ja) * | 2005-09-28 | 2007-04-05 | Konica Minolta Opto, Inc. | 射出成形装置 |
| WO2007133816A2 (en) * | 2006-01-10 | 2007-11-22 | Zymogenetics, Inc. | Methods of treating pain and inflammation in neuronal tissue using il-31ra and osmrb antagonists |
| TW200801513A (en) | 2006-06-29 | 2008-01-01 | Fermiscan Australia Pty Ltd | Improved process |
| DK2594586T3 (en) | 2006-09-01 | 2014-11-17 | Zymogenetics Inc | Monoclonal il-31 antibodies and methods of use thereof |
| US7799323B2 (en) | 2007-01-10 | 2010-09-21 | Zymogenetics, Inc. | Methods of using IL-31 to treat airway hyper-responsiveness and asthma |
| EP2796466B1 (en) * | 2007-12-07 | 2017-11-22 | ZymoGenetics, Inc. | Humanized antibody molecules specific for IL-31 |
-
2006
- 2006-02-14 US US11/353,454 patent/US20060188500A1/en not_active Abandoned
- 2006-02-14 CA CA2595939A patent/CA2595939C/en not_active Expired - Fee Related
- 2006-02-14 CA CA002595877A patent/CA2595877A1/en not_active Abandoned
- 2006-02-14 EP EP06735136A patent/EP1856150A2/en not_active Withdrawn
- 2006-02-14 MX MX2007009471A patent/MX2007009471A/es not_active Application Discontinuation
- 2006-02-14 WO PCT/US2006/005328 patent/WO2006088956A2/en not_active Ceased
- 2006-02-14 EP EP06735137.9A patent/EP1856539B1/en not_active Expired - Lifetime
- 2006-02-14 JP JP2007555370A patent/JP4927762B2/ja not_active Expired - Fee Related
- 2006-02-14 AU AU2006214325A patent/AU2006214325B2/en not_active Ceased
- 2006-02-14 WO PCT/US2006/005327 patent/WO2006088955A2/en not_active Ceased
- 2006-02-14 JP JP2007555369A patent/JP2008530137A/ja active Pending
- 2006-02-14 AU AU2006214326A patent/AU2006214326B2/en not_active Ceased
- 2006-02-14 MX MX2007009577A patent/MX2007009577A/es active IP Right Grant
- 2006-02-14 US US11/353,427 patent/US20060188499A1/en not_active Abandoned
-
2007
- 2007-07-19 IL IL184734A patent/IL184734A/en not_active IP Right Cessation
- 2007-07-23 IL IL184776A patent/IL184776A/en not_active IP Right Cessation
-
2008
- 2008-09-26 US US12/239,107 patent/US7723048B2/en not_active Expired - Lifetime
-
2009
- 2009-07-02 US US12/497,383 patent/US20090280121A1/en not_active Abandoned
-
2010
- 2010-03-19 US US12/727,912 patent/US8435745B2/en not_active Expired - Fee Related
-
2011
- 2011-04-26 US US13/094,482 patent/US8388964B2/en not_active Expired - Fee Related
-
2012
- 2012-04-15 IL IL219145A patent/IL219145A0/en unknown
-
2013
- 2013-01-30 US US13/754,278 patent/US20130177563A1/en not_active Abandoned
- 2013-03-13 US US13/799,048 patent/US8926957B2/en active Active
-
2015
- 2015-10-09 US US14/879,550 patent/US20160024201A1/en not_active Abandoned
-
2016
- 2016-12-20 US US15/384,774 patent/US20170096484A1/en not_active Abandoned
-
2018
- 2018-10-19 US US16/164,883 patent/US20190040125A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008530138A5 (https=) | ||
| Cai et al. | Uric acid induces endothelial dysfunction by activating the HMGB1/RAGE signaling pathway | |
| US9068988B2 (en) | Compositions and methods of detecting TIABs | |
| JP2008530137A5 (https=) | ||
| JP2017538671A5 (https=) | ||
| MY162024A (en) | Antagonistic human light-specific human monoclonal antibodies | |
| KR20200106053A (ko) | Atr 억제제를 사용한 암 치료 방법 | |
| JP2014523401A5 (https=) | ||
| BR112012008665A2 (pt) | tratamento de câncer | |
| NZ611117A (en) | Anti mif antibodies | |
| EP3076985B1 (en) | Composition comprising probiotics overexpressing clpb protein for use in the treatment of obesity | |
| WO2005044854A3 (en) | Antagonist anti-cd40 monoclonal antibodies and methods for their use | |
| JP2015525230A5 (https=) | ||
| Harvey et al. | Defensin DEFB103 bidirectionally regulates chemokine and cytokine responses to a pro-inflammatory stimulus | |
| JP2016523910A5 (https=) | ||
| JP2021181450A (ja) | 細胞内抗原に対して向けられた単一ドメイン抗体 | |
| ATE502305T1 (de) | Verwendung von vorstufen von enkephalinen und/oder deren fragmenten in der medizinischen diagnostik | |
| Kim et al. | xCT-mediated glutamate excretion in white adipocytes stimulates interferon-γ production by natural killer cells in obesity | |
| CN116970081B (zh) | 一种抗人源cd132的单克隆抗体及其应用 | |
| NZ591918A (en) | Antibodies to modified human igf-1/e peptides | |
| WO2010036031A3 (en) | Pauf-specific human monoclonal antibody, pharmaceutical composition for treating cancer comprising the same and method for detecting cancer using the same | |
| JP2013500739A5 (https=) | ||
| EP1778284A4 (en) | NUCLEIC ACIDS AND RELATED 58P1D12 PROTEINS FOR THE TREATMENT AND DETECTION OF CANCER | |
| JP2008516985A5 (https=) | ||
| JP2019531254A5 (https=) |